Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

Core Viewpoint - Clearside Biomedical, Inc. is set to report its fourth quarter and full year 2024 financial results on March 27, 2025, followed by a conference call to discuss the results and provide a corporate update [1]. Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on innovative delivery of therapies to the back of the eye through the suprachoroidal space (SCS) [3]. - The company utilizes its patented SCS Microinjector for a non-surgical procedure aimed at delivering various therapies to the macula, retina, or choroid, potentially improving vision in patients with serious eye diseases [3]. - Clearside is developing a pipeline of small molecule product candidates for administration via its SCS Microinjector, with its lead program, CLS-AX, in development for treating neovascular age-related macular degeneration (wet AMD) [3]. - The company has gained approval for its first product, XIPERE, which is available in the U.S. through a commercial partner [3]. - Clearside also partners strategically with other companies to utilize its SCS injection platform alongside other ophthalmic therapeutic innovations [3].